These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 31261624)

  • 1. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
    Tsai SF; Chen CH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
    Liou JH; Liu YM; Chen CH
    Transplant Proc; 2018 Oct; 50(8):2502-2505. PubMed ID: 30316386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
    EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
    Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
    Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
    Drucker DJ
    Cell Metab; 2018 Apr; 27(4):740-756. PubMed ID: 29617641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
    Sato T; Azuma Y; Ozone C; Okazaki M; Takeda A; Okada M; Futamura K; Hiramitsu T; Goto N; Narumi S; Watarai Y
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2597-2603. PubMed ID: 36974363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
    Thomas MC
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.
    Ertuglu LA; Porrini E; Hornum M; Demiray A; Afsar B; Ortiz A; Covic A; Rossing P; Kanbay M
    Transpl Int; 2021 Aug; 34(8):1341-1359. PubMed ID: 33880815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.